ArticleMicroorganisms2025
Protective Efficacy of an mRNA Vaccine Against HP-PRRSV Challenge in Piglets.
Article in Microorganisms, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A ubiquitinated E2-based mRNA vaccine confers complete protection against lethal challenge with classical swine fever virus.Journal of virology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global pork production sector continues to experience substantial financial burdens attributable to porcine reproductive and respiratory syndrome virus (PRRSV) infections. Despite the current epidemiological landscape in which NADC30-like strains predominate alongside cocirculating diverse PRRSV subtypes, highly pathogenic PRRSV (HP-PRRSV) remains a persistent threat. Furthermore, currently available commercial PRRS vaccine formulations exhibit restricted heterologous protection efficacy. The development of novel mRNA-based vaccines represents a promising strategy for PRRS mitigation protocols. In response to these epidemiological challenges, an HP-PRRSV strain (Lineage 8), designated as JX021, was isolated and characterized in this study. Pathogenicity experiments confirmed that JX021 induces severe clinical symptoms in piglets. Moreover, by combining immunoinformatics and literature-guided approaches, critical antigenic epitopes on HP-PRRSV (represented by the JXA1 strain) structural proteins were identified, enabling the design and synthesis of a multiepitope mRNA vaccine. The survival of piglets immunized with the mRNA vaccine was higher than that of the inactivated vaccine immunization group and the PBS group. Compared with the inactivated vaccine group, the mRNA vaccine group presented reductions in viremia and lung lesions. These findings provide new insights into the design and development of further PRRS vaccine research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.